Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $28,310.37 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 709 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $28,310.37. Following the completion of the sale, the insider now owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Dennis Cho also recently made the following trade(s):

• On Tuesday, July 2nd, Dennis Cho sold 126 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $6,048.00.
• On Thursday, June 20th, Dennis Cho sold 234 shares of Twist Bioscience stock. The stock was sold at an average price of $49.41, for a total transaction of $11,561.94.
• On Friday, June 14th, Dennis Cho sold 95 shares of Twist Bioscience stock. The shares were sold at an average price of $51.04, for a total value of $4,848.80.
• On Thursday, June 6th, Dennis Cho sold 276 shares of Twist Bioscience stock. The stock was sold at an average price of $51.33, for a total transaction of $14,167.08.

Twist Bioscience Price Performance

Shares of TWST stock traded down $1.64 on Wednesday, hitting $44.60. 1,109,494 shares of the company’s stock were exchanged, compared to its average volume of 1,052,113. The company has a 50 day moving average of $50.72 and a 200 day moving average of $41.58. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90. The stock has a market cap of $2.60 billion, a P/E ratio of -13.27 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. Twist Bioscience’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same period in the previous year, the company earned ($1.01) EPS. Sell-side analysts predict that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TWST shares. Guggenheim began coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday. The Goldman Sachs Group boosted their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Barclays reduced their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday. Finally, TD Cowen raised their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $48.22.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TWST. BNP Paribas Financial Markets increased its position in Twist Bioscience by 34.8% in the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock valued at $5,895,000 after acquiring an additional 44,349 shares during the period. UBS Group AG raised its position in shares of Twist Bioscience by 106.4% during the fourth quarter. UBS Group AG now owns 213,467 shares of the company’s stock worth $7,868,000 after acquiring an additional 110,036 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its stake in shares of Twist Bioscience by 2.9% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after acquiring an additional 99,511 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in Twist Bioscience in the first quarter valued at approximately $300,000. Finally, SageView Advisory Group LLC bought a new position in Twist Bioscience during the 1st quarter worth approximately $1,144,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.